An Analysis of Safety Data from Five Phase III Clinical Trials on the Use of Botulinum Neurotoxin Type A-ABO for the Treatment of Glabellar Lines

Aesthetic Surgery Journal

Volumn 29, Issue 6 SUPPL., 2009, Pages

  Rubin, Mark ^a   Dover, Jeffrey ^a   Maas, Corey ^a   Nestor, Mark ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ARTICLE; BLEPHAROSPASM; CLINICAL TRIAL; CUTIS LAXA; DATA ANALYSIS; DIZZINESS; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; ECCHYMOSIS; EYELID EDEMA; GENDER; GLABELLAR FACIAL LINE; HUMAN; INFLUENZA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE REACTION; META ANALYSIS; MULTIPLE CYCLE TREATMENT; MUSCLE MASS; PRIORITY JOURNAL; PTOSIS; QT PROLONGATION; RHINOPHARYNGITIS; SIDE EFFECT; SINUS HEADACHE; SINUSITIS; STREPTOCOCCAL PHARYNGITIS; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; VOMITING; WRINKLE;

ADULT; BOTULINUM TOXIN TYPE A; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; ELECTROCARDIOGRAM PATTERN; FEMALE; HUMANS; MALE; NEUROTOXINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; SKIN AGING; THERAPIES, INVESTIGATIONAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 71549119470     PISSN: 1090820X     EISSN: 1527330X     Source Type: Journal    
DOI: 10.1016/j.asj.2009.09.010     Document Type: Article

References (17)

1. American Society for Aesthetic Plastic Surgery website. Cosmetic Surgery National Data Bank statistics 2008. (Accessed August 29, 2009, at http://www.surgery.org/sites/default/files/2008stats.pdf)
2. Olver J.M. Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease. Br J Ophthalmol 82 (1998) 528-533
3. Carruthers J.A., Lowe N.J., Menter M.A., et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46 (2002) 840-849
4. Rzany B., Dill-Muller D., Grablowitz D., Heckman M., Caird D., and German-Austrian Retrospective Study Group. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg 33 1 spec no. (2007) S18-S25
5. Botox (botulinum toxin type A) [package insert] (October 2006), Allergan, Irvine, CA
6. Botox Cosmetic (botulinum toxin type A) [package insert] (April 2008), Allergan, Irvine, CA
7. Dysport (abobotulinum toxin A) [package insert] (April 2009), Medicis Aesthetics, Scottsdale, AZ
8. Myobloc (botulinum toxin type B) [package insert] (November 2004), Solstice Neurosciences, San Francisco, CA
9. Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., and Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 51 (2004) 223-233
10. Lowe P.L., Patnaik R., and Lowe N.J. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: double-blind, randomized study. J Am Acad Dermatol 55 (2006) 975-980
11. Monheit G., Carruthers A., Brandt F., and Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 33 1 spec no. (2007) S51-S59
12. Rubin M.G., Dover J.S., Glogau R.G., Goldberg D.J., Goldman M.P., and Schlessinger J. The efficacy and safety of a new US botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol 8 (2009) 439-444
13. Brandt F., Swanson N., Baumann L., and Huber B. A randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. Dermatol Surg (2009 June 22) [Epub ahead of print].
14. Kane MAC, Brandt F, Rohric RJ, Narins RF, Monheit GC, Huber BM, Reloxin Investigational Group. Evaluation of variable-dose treatment with a new US botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase 3, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg [in press].
15. Moy R., Maas C., Monheit G., Huber M.B., and Reloxin Investigational Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 11 (2009) 77-83
16. Cohen J.L., Schlessinger J., Cox S.E., and Lin X. An analysis of the long-term safety data of repeat administrations of Botulinum Neurotoxin Type A-ABO for the treatment of glabellar lines. Aesthet Surg J 29 (2009) S43-S49
17. Tang-Liu D.D., Aoki K.R., Dolly J.O., et al. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 42 (2003) 461-469